Welcome to our dedicated page for Organogenesis Hldgs SEC filings (Ticker: ORGO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Organogenesis Holdings Inc.'s SEC filings document a regenerative medicine issuer with Class A common stock listed on the Nasdaq Capital Market. The filings cover operating and financial results for Advanced Wound Care and Surgical & Sports Medicine products, including furnished 8-K earnings releases that separate product revenue by market category.
The company's regulatory record also includes proxy materials for annual meeting matters, director elections, advisory voting items, board governance and compensation disclosures. Other filings address Regulation FD and material-event updates for ReNu clinical and regulatory matters, capital-structure details involving Class A common stock and Series A Convertible Preferred Stock voting mechanics, and risk and governance topics tied to its product portfolio.
Organogenesis Holdings Inc. President and CEO Gary S. Gillheeney reported updated equity compensation activity. On February 18, 2026, he acquired 188,856 shares of Class A common stock as a grant or award at $0.00 per share, and disposed of 91,311 shares at $3.84 per share to cover tax obligations. The amendment corrects the numbers previously reported for the performance share vesting and related tax-withholding, with no other changes to the original Form 4.
Organogenesis Holdings Inc. Chief Commercial Officer Brian Grow filed an amended insider transaction report. On February 18, 2026, he acquired 48,818 shares of Class A common stock at $0.00 per share through the vesting and settlement of a performance share award, and 11,887 shares were disposed of at $3.84 per share to cover tax obligations. After these adjustments, he directly owns 899,724 shares. The amendment corrects the previously reported share amounts related to this award, with no other changes.
Organogenesis Holdings Inc. Chief Operating Officer Patrick Bilbo filed an amended insider report updating a prior Form 4. The amendment corrects the number of Class A Common Stock shares reported from a performance share award that vested on February 18, 2026 and the related tax withholding. The filing now shows an award acquisition of 49,102 shares at a stated price of $0.00 per share and a tax-withholding disposition of 16,375 shares at $3.84 per share. Following these adjustments, Bilbo directly holds 1,128,312 shares of Class A Common Stock.
Organogenesis Holdings Inc. Chief Financial Officer Francisco David reported amended equity award details. On February 18, 2026, he acquired 44,040 shares of Class A common stock as a grant at no cost, and 14,687 shares were withheld at $3.84 per share to cover tax obligations. This amendment only corrects the share counts previously reported for the award vesting and related tax withholding.
Organogenesis Holdings Inc. executive Robert Cavorsi, Vice President of Strategy, filed an amended insider report updating a prior Form 4. The amendment corrects the number of Class A Common Stock shares acquired upon vesting and settlement of a performance share award and the shares withheld for taxes. On February 18, 2026, he was granted 16,454 shares at $0.00 per share and had 5,487 shares withheld at $3.84 per share to satisfy tax obligations. Following these adjustments, his direct holdings total 276,224 Class A shares. The filing states no other changes were made to the original report.
Organogenesis Holdings Inc. executive Lori Freedman updated her insider holdings following a performance share award. She acquired 43,212 shares of Class A common stock at no cost from the vesting and settlement of a performance share award, and 14,411 shares were withheld to cover related tax obligations. This amended Form 4 corrects the originally reported acquired and tax-withheld share amounts, with no other changes to the prior filing.
Organogenesis Holdings Inc. filed an initial ownership statement for Chief Accounting Officer Patrick McGuire, detailing his direct holdings of Class A common stock and related equity awards. The filing notes that some positions represent restricted stock units granted under the 2018 Equity Incentive Plan, with unvested RSUs scheduled to vest in equal annual installments on December 29, 2026, 2027 and 2028, and on February 15, 2027, 2028 and 2029.
Organogenesis Holdings Inc. provides an in‑depth look at its regenerative medicine business, focused on advanced wound care and surgical and sports medicine products like Apligraf, Dermagraft, PuraPly, NuShield, Affinity, Novachor and ReNu.
The company outlines major shifts in Medicare and CMS policy for skin substitutes, including new 2026 payment structures and the WISeR prior‑authorization model, which are already contributing to a significant year‑over‑year revenue decline in early 2026 and may pressure future utilization and profitability.
Organogenesis also highlights mixed but generally supportive Phase 3 data for its ReNu osteoarthritis program and the start of a rolling BLA, plus a long‑term lease for a new Smithfield, Rhode Island biomanufacturing facility intended to bring Dermagraft production back online and expand capacity from 2027.
Organogenesis Holdings Inc. reported record results for 2025, driven by strong growth in advanced wound care. Net product revenue for the year reached $563.0 million, up 17% from 2024, with advanced wound care contributing $531.2 million. Net income improved to $37.0 million from $0.9 million, and Adjusted EBITDA nearly doubled to $98.1 million.
In the fourth quarter of 2025, net product revenue rose 78% to $225.1 million, and net income jumped to $43.7 million. Gross margin remained strong at 76% for the year. The company ended 2025 with $94.3 million in cash, cash equivalents and restricted cash and no outstanding debt obligations.
For 2026, management expects total net revenue between $350.0 million and $420.0 million, a decline of 25% to 38% from total net revenue of $564.2 million in 2025. The company anticipates a sharp revenue drop in early 2026 due to CMS reimbursement and coverage changes for skin substitutes, followed by stronger quarter-over-quarter growth later in the year and a return to more “normalized” growth in 2027.
Organogenesis Holdings Inc. has appointed Patrick McGuire, 40, as Chief Accounting Officer and principal accounting officer, effective February 18, 2026. His annual base salary was increased to $345,000, with no other changes to his compensation.
McGuire previously served as the company’s Vice President, Corporate Controller since September 2023 and earlier was Corporate Controller at Cynosure, LLC and a director at PricewaterhouseCoopers LLP. There are no family relationships or related-party transactions requiring disclosure. Concurrently, David Francisco ceased serving as principal accounting officer but continues as Chief Financial Officer and principal financial officer.